Expertise in
18
conditions

Dr. Srdan Verstovsek

Oncology
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 
Clinical Trials:Currently Recruiting for 1 Trial
30 Years of Experience
Expertise in
18
conditions
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 

Overview

Srdan Verstovsek is an Oncologist practicing medicine in Cary, North Carolina. He has been practicing medicine for over 30 years.

Dr. Verstovsek is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Myeloproliferative Neoplasms (MPN), Leukemia, Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 472 peer reviewed articles and participating in 9 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

UT MD Anderson Cancer Center
210 Ashville Ave # 408, Cary, NC 27518

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 2 Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis
A Phase 2 Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis
Enrollment Status: Recruiting
Publish Date: May 10, 2024
Intervention Type: Drug
Study Drug: TL-895
Study Phase: Phase 2
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Enrollment Status: Completed
Publish Date: November 18, 2025
Intervention Type: Drug
Study Phase: Phase 2
Open-Label Roll-Over Study to Assess the Long-Term Safety and Efficacy of Ruxolitinib in Subjects With Myelofibrosis
Open-Label Roll-Over Study to Assess the Long-Term Safety and Efficacy of Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Other, Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Drug, Biological
Study Drug: PEG-IFN-Alpha-2b
Study Phase: Phase 3
PEG IFN-alpha2a (Pegasys®) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia)
PEG IFN-alpha2a (Pegasys®) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia)
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Drug
Study Drug: IFN-alpha2a
Study Phase: Phase 2
An Open-label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 (a LOXL2 Inhibitor) in Participants With Myelofibrosis (MF)
An Open-label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 (a LOXL2 Inhibitor) in Participants With Myelofibrosis (MF)
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2024
Intervention Type: Drug
Study Drug: GB2064
Study Phase: Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia
A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 2
Phase 2 Study of Nivolumab in Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
Phase 2 Study of Nivolumab in Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
Enrollment Status: Terminated
Publish Date: May 15, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
View 8 Less Clinical Trials

472 Total Publications

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.
POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.
Journal: Future oncology (London, England)
Published: March 07, 2026
Similar Doctors
Expertise in
27
conditions
Dr. Alessandra Ferrajoli
Oncology
Expertise in
27
conditions
Dr. Alessandra Ferrajoli
Oncology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.4 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances

Alessandra Ferrajoli is an Oncologist practicing medicine in Cary, North Carolina. Dr. Ferrajoli is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
29
conditions
Dr. Anthony Conley
Oncology
Expertise in
29
conditions
Dr. Anthony Conley
Oncology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.4 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anthony Conley is an Oncologist practicing medicine in Cary, North Carolina. Dr. Conley is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Chondrosarcoma, Alveolar Soft Part Sarcoma, Liposarcoma, and Salpingo-Oophorectomy.

Expertise in
18
conditions
Dr. Michelle Fanale
Oncology
Expertise in
18
conditions
Dr. Michelle Fanale
Oncology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.4 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances

Michelle Fanale is an Oncologist practicing medicine in Cary, North Carolina. Dr. Fanale is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, T-Cell Lymphoma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Srdan Verstovsek

How do I make an appointment with Dr. Srdan Verstovsek?

You can book an appointment with Dr. Srdan Verstovsek by calling their office at 713-792-6161. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Srdan Verstovsek a top-rated expert for Myeloproliferative Neoplasms (MPN)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Srdan Verstovsek is classified as an Elite expert for Myeloproliferative Neoplasms (MPN), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Srdan Verstovsek specialize in?

While Dr. Srdan Verstovsek is a Oncology, they have specific expertise in Myeloproliferative Neoplasms (MPN), Leukemia, and Acute Myeloid Leukemia (AML). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Srdan Verstovsek participate in research or clinical trials?

Yes. Dr. Srdan Verstovsek has published 472 articles and abstracts on conditions like Myeloproliferative Neoplasms (MPN). You can view a list of Dr. Srdan Verstovsek's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Srdan Verstovsek accept my insurance?

Dr. Srdan Verstovsek accepts most major insurance plans, including Aetna and Humana. We recommend calling the office directly at 713-792-6161 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Verstovsek's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile